Glycoengineered CD20 Antibody Obinutuzumab Activates Neutrophils and Mediates Phagocytosis Through CD16B More Efficiently Than Rituximab.
Golay J, Da Roit F, Bologna L et al.
Key Points:
Obinutuzumab (GA101) anti-CD20 antibody with higher binding affinity for CD16A than rituximab (RTX).
Investigated binding of obinutuzumab to CD16B and its functional activity compared to rituximab.
Glycoengineered rituximab or obinutuzumab bound to CD16B with about 7-fold higher affinity, compared to non-glycoengineered antibodies.
Implications:
- Obinutuzumab mediates phagocytosis of CLL targets by PMN through higher binding affinity for CD16B compared to RTX.
View the original abstract on the ASH website.
